FDMT - CIK 0001650648
4D Molecular Therapeutics, Inc. trades as FDMT. In its fiscal 2025 annual report the company posted revenue of $85.21M, up 230194.6% from the prior year and net income of -$140.11M. This page tracks 4D Molecular Therapeutics, Inc. through 397 SEC filings, with financial statements and metrics updated as new reports are filed.
Over the last 6 fiscal years 4D Molecular Therapeutics, Inc.'s revenue grew from $6.99M to $85.21M, a compound annual growth rate of 51.7%. Net profit margin expanded from -705.8% to -164.4% over the same period - every figure below comes from the company's audited annual filings.
| Filing | Type | Filed |
|---|---|---|
| SCHEDULE 13G/A | - | 2026-05-15 |
| SCHEDULE 13G/A | - | 2026-05-15 |
| EFFECT | - | 2026-05-13 |
| SCHEDULE 13G | - | 2026-05-12 |
| Securities registration | S-3 | 2026-05-07 |
| Quarterly report | 10-Q | 2026-05-07 |
| Major company event | 8-K | 2026-05-07 |
| Annual report to shareholders | ARS | 2026-04-28 |
The largest companies sharing 4D Molecular Therapeutics, Inc.'s SEC industry classification (biological products, (no diagnostic substances)).
4D Molecular Therapeutics, Inc. reported revenue of $85.21M for fiscal year 2025, an increase of 230194.6% year over year.
In its latest fiscal year 4D Molecular Therapeutics, Inc. reported a net loss of $140.11M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.